  | Kirkove, D.* , STREEL, S.* , ORY, A., AUBOUY, G., DE JODE, E., JERUSALEM, G., GAGNAYRE, R., & Pétré, B. (May 2022). Immuno’Act - J’agis sur les effets secondaires liés à mon immunothérapie oncologique [Poster presentation]. Congrès Éducation Thérapeutique du Patient 2022, Montpellier, France.  Editorial reviewed* These authors have contributed equally to this work. |
  | Poiré, X., Graux, C., ORY, A., Herman, J., Baron, F., Schoemans, H., Lewalle, P., De Becker, A., Deeren, D., Berneman, Z., Kerre, T., Zachée, P., Selleslag, D., & Beguin, Y. (2022). Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS). Bone Marrow Transplantation, 57, 116-118. doi:10.1038/s41409-021-01464-x Peer Reviewed verified by ORBi |
 | Servais, S., Baron, F., LECHANTEUR, C., SEIDEL, L., Selleslag, D., Maertens, J., BAUDOUX, E., Zachee, P., Van Gelder, M., Noens, L., Kerre, T., Lewalle, P., Schroyens, W., ORY, A., & Beguin, Y. (2018). Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graftversus- host disease: A multicenter prospective study. Oncotarget, 9 (29), 20590-20604. doi:10.18632/oncotarget.25020 Peer Reviewed verified by ORBi |
 | HANNON, M., BEGUIN, Y., Ehx, G., SERVAIS, S., SEIDEL, L., Graux, C., Maertens, J., Kerre, T., Daulne, C., de Bock, M., Fillet, M., ORY, A., WILLEMS, E., GOTHOT, A., Humblet-Baron, S., & BARON, F. (15 July 2015). Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning. Clinical Cancer Research, 21 (14), 3131-9. doi:10.1158/1078-0432.CCR-14-3374 Peer Reviewed verified by ORBi |
 | Baron, F., Zachée, P., Maertens, J., Kerre, T., ORY, A., SEIDEL, L., Graux, C., Lewalle, P., Van Gelder, M., Theunissen, K., WILLEMS, E., Emonts, M.-P., De Becker, A., & Beguin, Y. (2015). Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. Journal of Hematology and Oncology, 8, 4. doi:10.1186/s13045-014-0098-9 Peer Reviewed verified by ORBi |
 | BEGUIN, Y., ZACHEE, P., MAERTENS, J., KERRE, T., ORY, A., SEIDEL, L., GRAUX, C., LEWALLE, P., VAN GELDER, M., THEUNISSEN, K., WILLEMS, E., EMONDS, M.-P., DE BECKER, A., & BARON, F. (December 2014). Nonmyeloablative allogeneic hematopoietic cell transplantation following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. Blood, 124 (21), 542. Peer Reviewed verified by ORBi |